Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at chemotherapy for people with advanced T cell lymphoma of the skin (EORTC 21012)
This trial looked at liposomal doxorubicin for people with an advanced T cell lymphoma of the skin called mycosis fungoides.
Cutaneous T cell lymphomas (CTCL) are types of non Hodgkin lymphoma that affect the skin. Mycosis fungoides is the most common of these, although it is still rare.
Doctors can use a number of different ways to treat CTCL. They usually use a combination of chemotherapy drugs to treat advanced CTCL. But this can have severe side effects.
Doctors thought that liposomal doxorubicin (Caelyx, Myocet or Doxil) may work as well on its own and have fewer side effects.
The aims of this trial were to find out
- How well liposomal doxorubicin worked for mycosis fungoides CTCL
- More about the side effects
Summary of results
The researchers found that liposomal doxorubicin might work well for people with advanced mycosis fungoides CTCL.
This study recruited 49 people. Everyone had liposomal doxorubicin.
After completing their treatment, 20 of the 49 people had responded. Of these 20 people, for
- 3 there was no sign of their mycosis fungoides –
- 17 their mycosis fungoides had shrunk –
The main side effects were
The researchers concluded that liposomal doxorubicin looked promising as a treatment for mycosis fungoides CTCL. And it should be looked at in further clinical trials.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sean Whittaker
European Organisation for Research and Treatment of Cancer (EORTC)